Navigation Links
Rejected Alzheimer's drug shows new potential
Date:7/31/2012

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease. The findings, published July 31, 2012 in Molecular Psychiatry, demonstrate renewed potential for this compound and could lead to clinical trials in patients with early stages of the disease.

Latrepirdine, known commercially as Dimebon, was initially sold as an antihistamine in Russia, approved for use there in 1983. In the 1990s, researchers at the Institute of Physiologically Active Compounds in Moscow determined that the compound appeared effective in treating Alzheimer's disease in animals. They continued their research in humans and performed several studies, including Phase I and II trials, all of which showed significant and sustained improvement in cognitive behavior with minimal side effects. The Phase II trials, performed in Russia, were overseen by U.S. Alzheimer's researchers, including Mary Sano, PhD, Director of the Mount Sinai Alzheimer's Disease Research Center.

However, when research was continued in the United States in a Phase III trial, the drug did not demonstrate any improvement in people with the disease, causing the sponsors to halt further clinical study of the drug in Alzheimer's disease. Some researchers have speculated that the Russian patients might have had different disease stage or subtype of Alzheimer's, and therefore were more responsive to treatment than the patients in the Phase III trials in the United States.

Before the failed trials were announced, researchers at Mount Sinai School of Medicine, led by Sam Gandy, MD, PhD, Professor of Neurology, and Psychiatry, and Director of the Mount Sinai Center for Cognitive Health, began studying the mechanism of act
'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gay Adults Rejected by Parents Have Worse Health, Study Finds
2. Landmark HIV treatment-as-prevention study shows additional health benefits, cost-effectiveness
3. Weight Control Can Cut Womens Diabetes Risk, Study Shows
4. Mindfulness meditation reduces loneliness in older adults, Carnegie Mellon study shows
5. SEARCH study shows 1-year drop in HIV virus levels in rural Ugandan parish after campaign
6. Research shows potential of microneedles to target therapeutics to the back of the eye
7. 32-country study shows that type 2 diabetes drug is clinically effective for long-term use
8. Benefits of HIV drugs rise -- but less than previously believed, Penn study shows
9. Alzheimers Drug Shows Promise in Early Trial
10. Study shows colon and rectal tumors constitute a single type of cancer
11. Spouses of severe-sepsis patients at high risk of depression, U-M study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Vegas, NV (PRWEB) February 28, 2015 My ... will be sending a team to Las Vegas, Nevada for ... Market Week is one of the leading consumer-goods tradeshows and ... vendors at this year’s event. My Shiney Hiney can be ... a fresh, modern design for the at-home personal hygiene brush ...
(Date:2/27/2015)... 27, 2015 Wireless Analytics, ... and one of the founders of the ... Bell Mobility within their CLEAN Platform™ (Communications Lifecycle ... Wireless Analytics’ newly developed Bell Mobility Data Loader ... Canadian wireless carrier’s business customers. , Wireless Analytics ...
(Date:2/27/2015)... Just a little over two years ago, ... Sjögren’s Syndrome after a new autoantibody associated with the ... of Buffalo and Immco Diagnostics, Inc. After the groundbreaking ... a new diagnostic test that would be ... Researchers aimed to develop a test that would more ...
(Date:2/27/2015)... On March 2-4, the Mesothelioma Applied ... Institute (NCI) will co-host the annual International Symposium ... Health (NIH), in Bethesda, Maryland. The event comprises ... professionals and scientists who specialize in mesothelioma, while ... including patients, their families, and caregivers. , The ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Altec Products, ... as their Sage ERP Document Management Partner of the ... ERP, Sage CRM and other complimentary solutions for their ... worked side-by-side for many years to provide clients with ... applications. , “We are thrilled to recognize ADSS ...
Breaking Medicine News(10 mins):Health News:My Shiney Hiney® to Participate in ASD Market Week 2015 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Breakthrough Blood Test for Early Detection of Sjögren’s Syndrome Now Available 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Altec Announces 2014 Sage ERP Document Management Partner of the Year Award Recipient 2
... , , SOUTHBOROUGH, Mass., Aug. 26 ... toll worldwide this season, and experts say the new flu strain is expected ... end up being affected by the H1N1 flu, the C ... H1N1 alert to pandemic status, its highest level. What does this mean ...
... LOS ANGELES, Aug. 26 Sports-related eye injuries are a leading cause ... hard blow to the eye, they should be examined, even if there ... educate the public about vision protection, The Vision Center at Childrens Hospital ... this September. , , According to Dr. Mark ...
... , SMITHFIELD, R.I., Aug. 26 A series of free ... of employer-based Hearing Conservation Programs have been announced for eight cities along the ... L eight (R)/ Sperian Hear i ng Protection ... HearForever(TM): Be s t Practices ...
... , SARASOTA, Fla., Aug. 26 ... that it proposes to offer, subject to market and other considerations, senior ... rate, principal amount and maturity, will depend on market conditions at the ... sale of the notes will be used to repay borrowings under Roper,s ...
... Cancer Metastasis Dr. Amanda Harvey and colleagues at ... role in breast cancer progression and dissemination. Their report ... American Journal of Pathology . Breast ... cancer patients. Non-metastatic breast cancer cells rely on interactions ...
... , , , ... Medical, Inc. (Nasdaq: SLTM ) today announced the launch ... large body areas during a single treatment. Prior to the non-ablative ... to the face. The Fraxel re:store Dual takes the industry leading ...
Cached Medicine News:Health News:Monitoring for Fever Can Help With Early Detection of H1N1 - 'Swine Flu' 2Health News:September is Vision Safety Month at the Vision Center CHLA: Sports Eye Injuries a Leading Cause of Blindness in Children 2Health News:September is Vision Safety Month at the Vision Center CHLA: Sports Eye Injuries a Leading Cause of Blindness in Children 3Health News:Free Seminars Will Detail Best Practices in Employer Hearing Conservation, Impending NRR Change 2Health News:Free Seminars Will Detail Best Practices in Employer Hearing Conservation, Impending NRR Change 3Health News:Free Seminars Will Detail Best Practices in Employer Hearing Conservation, Impending NRR Change 4Health News:Roper Industries Announces Proposed Public Offering of Senior Unsecured Notes due 2019 2Health News:Roper Industries Announces Proposed Public Offering of Senior Unsecured Notes due 2019 3Health News:Tips from the American Journal of Pathology 2Health News:Tips from the American Journal of Pathology 3Health News:Tips from the American Journal of Pathology 4Health News:Tips from the American Journal of Pathology 5Health News:Solta Medical Launches New Fraxel re:store(R) Dual Laser System 2Health News:Solta Medical Launches New Fraxel re:store(R) Dual Laser System 3
(Date:2/27/2015)... Pa. , Feb. 27, 2015  In recognition ... ongoing commitment to the global bleeding disorders community, ... 2 million international units (IUs) of protein therapies to ... international not-for- profit organization which has worked to improve ... bleeding disorders. The donation supports the WFH,s Global Alliance ...
(Date:2/27/2015)... TEL-AVIV, Israel , February 27, 2015 ... Unternehmen baut sein bahnbrechendes Überwachungssystem für kongestive ... weiter aus -   ... Medical Technologies, die ein neuartiges Herzüberwachungssystem für ... gab heute bekannt, dass sie ein Finanzierungsvorhaben ...
(Date:2/27/2015)... YORK , Feb. 27, 2015 /PRNewswire/ ... are increasing in applications as their effectiveness ... firm Kalorama Information.  Kalorama Information says that ... is the most powerful tool in proteomic ... spec; MS) through its traditional techniques has ...
Breaking Medicine Technology:CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3
... A new study looking at in-person, electronic, telephonic, fax ... their medications concludes that pharmacists at a retail store ... patients to take medicine as prescribed. (Logo: ... of more than 40 years of studies published in ...
... 21, 2010 Takeda Pharmaceutical Company Limited ("Takeda") ... Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed ... against the companies in response to their Abbreviated ... HCl), ACTO plus met® (pioglitazone HCl and ...
Cached Medicine Technology:New Study Finds Pharmacists and Nurses are the Most Effective Health Care 'Voices' in Promoting Medication Adherence 2New Study Finds Pharmacists and Nurses are the Most Effective Health Care 'Voices' in Promoting Medication Adherence 3Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 2Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 3Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 4Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 5Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 6
... is an automated blood gas analysis system ... reduce the steps in the analytical process, ... errors. The 1st automatic system consists of ... and FLEXQ automatic sample handling system. With ...
... RAPID Reader - Portable RAPIDViewing Software., ... Given Diagnostic System, which can be installed on ... to open Patient RAPID Report (PRR) videos created ... to save them, at home or on the ...
... is a unique tool that ... commands to activate shortcut keys ... the need to perform manual ... can devote your full attention ...
... Application for POLYGRAM NET™ (PNET) works ... to record and analyze pressure and ... The PNET software and Polygraf ID ... as well as self-adhesive cutaneous and ...
Medicine Products: